Monitoring γ -H2AX levels in a patient's circulating tumor cells (CTCs) following cancer treatment has been evaluated and may be a promising technique for following the pharmacodynamic effects of anticancer therapies [23]. The gene discussed is H2AX; the disease is neoplasm.